Loading...
Vismodegib in the treatment of advanced BCC
O’Kane, GM Lyons, T McDonald, I Mulligan, N Moloney, FJ Murray, D Kelly, CM
O’Kane, GM
Lyons, T
McDonald, I
Mulligan, N
Moloney, FJ
Murray, D
Kelly, CM
Advisors
Editors
Other Contributors
Departments
Date
2014-07
Date Submitted
Keywords
SKIN CANCER
Other Subjects
Subject Mesh
Planned Date
Start Date
Collaborators
Principal Investigators
Files
Loading...
Main Article
Adobe PDF, 6.19 KB
Alternative Titles
Publisher
Abstract
Basal-cell carcinoma (BCC) is the most commonly diagnosed malignancy, comprising over 80%of non-melanoma skin cancers. Surgical excision is adequate treatment for most BCCâ s. Options are however limited for the minority of patients presenting with locally advanced inoperable or metastatic BCC. The Hedgehog signalling pathway is a critical driver in the pathogenesis of both sporadic and hereditary BCC. On 31st January 2012, based on a phase II clinical trial the US Food and Drug Administration approved Vismodegib (Erivedgefi, Roche) a first-in-class, small-molecule oral Hedgehog-inhibitor for the treatment of locally advanced inoperable and metastatic BCC. We present our experience treating the first Irish patient with this agent.
Language
en